Danielle Malchow
Nurse Practitioner · Hastings, NENPI 1629450051
Payments from drug & device makers
Across 253 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$280
- Lilly USA, LLC$278
- Pfizer$240
- Otsuka America Pharmaceutical, Inc.$228
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$141
- plus $978 from 24 others
What the payments were for
- Food & beverage$3,822100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $1,678 |
| Novo Nordisk | 20 | $280 |
| Lilly USA, LLC | 22 | $278 |
| Pfizer | 16 | $240 |
| Otsuka America Pharmaceutical, Inc. | 11 | $228 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $141 |
| Exact Sciences | 6 | $92 |
| Johnson & Johnson | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $76 |
| Bayer | 5 | $73 |
| Amgen | 5 | $67 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Merck | 4 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Boehringer Ingelheim | 3 | $43 |
| GSK | 3 | $38 |
| Abiomed | 1 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Gilead | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Organon | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Dexcom, Inc. | 1 | $11 |
How this compares
$3,822 in reported general payments places this provider in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $25,600 |
| XareltoRivaroxaban | 15 | $14,158 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,472 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,366 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,432 |
| FarxigaDapagliflozin Propanediol | 17 | $8,629 |
| EntrestoSacubitril/Valsartan | 14 | $4,814 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,951 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,578 |
| Potassium Chloride | 123 | $2,133 |
| Gabapentin | 135 | $1,973 |
| Atorvastatin Calcium | 227 | $1,885 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 24 | $1,676 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,301 |
| Fluticasone Propionate | 63 | $1,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $280 | $25,60026 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $38 | $24,41648 claims |
| Johnson & JohnsonXarelto | $76 | $14,15815 claims |
| NovartisEntresto | $14 | $4,81414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Hastings
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Jodi FuehrerGrand Island$25K
- Amanda GuggenmosOmaha$23K
- Lisa OstendorfLincoln$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.